Rohto Aims to Enter Field of Regenerative Medicine by 2020, with Initial Focus on Fibrotic Diseases

February 25, 2016
Rohto CEO Kunio Yamada Rohto Pharmaceutical aims to launch regenerative medicine products in the field of fibrotic diseases such as hepatic cirrhosis by 2020. The company will initiate its first clinical trials later this year or early next year. Chairman...read more